Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 31 entries
View as:

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01903460 Org: User:
Start: 08/31/13 End: 03/31/15 Due: 03/31/16

Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis

Phase: N/A Priority: Normal
NCT ID: NCT01438411 Org: User:
Start: 01/31/10 End: 07/31/16 Due: 07/31/17

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02117713 Org: User:
Start: 03/16/15 End: 06/01/20 Due: 06/01/21

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)

Phase: N/A Priority: Normal
NCT ID: NCT02160782 Org: User:
Start: 10/28/14 End: 05/28/20 Due: 05/28/21

Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis

Phase: N/A Priority: Normal
NCT ID: NCT01115582 Org: User:
Start: 04/30/10 End: 08/31/10 Due: 08/31/11

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

Phase: N/A Priority: Normal
NCT ID: NCT04718961 Org: User:
Start: 01/04/21 End: 12/07/22 Due: 12/07/23

Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid

Phase: N/A Priority: Normal
NCT ID: NCT00007020 Org: User:
Start: 01/31/92 End: 12/31/09 Due: 12/31/10

An Extension Study of Maralixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

Phase: N/A Priority: Normal
NCT ID: NCT04185363 Org: User:
Start: 01/08/20 End: 03/31/25 Due: 03/31/26

The REPLACE Registry for Cholbam® (Cholic Acid)

Phase: N/A Priority: Normal
NCT ID: NCT03115086 Org: User:
Start: 07/10/17 End: 07/31/39 Due: 07/31/40

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

Phase: N/A Priority: Normal
NCT ID: NCT02287779 Org: User:
Start: 01/19/15 End: 06/19/15 Due: 06/19/16

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

Phase: N/A Priority: Normal
NCT ID: NCT03905330 Org: User:
Start: 07/09/19 End: 09/01/22 Due: 09/01/23

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Phase: N/A Priority: Normal
NCT ID: NCT05050136 Org: User:
Start: 09/22/21 End: 12/31/25 Due: 12/31/26

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Phase: N/A Priority: Normal
NCT ID: NCT04663308 Org: User:
Start: 12/18/20 End: 12/31/25 Due: 12/31/26

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

Phase: N/A Priority: Normal
NCT ID: NCT02475317 Org: User:
Start: 06/01/15 End: 12/01/15 Due: 12/01/16

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

Phase: N/A Priority: Normal
NCT ID: NCT02061540 Org: User:
Start: 03/31/14 End: 02/29/16 Due: 02/28/17

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

Phase: N/A Priority: Normal
NCT ID: NCT04524390 Org: User:
Start: 07/08/21 End: 02/07/24 Due: 02/07/25

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02321306 Org: User:
Start: 05/31/15 End: 03/31/18 Due: 03/31/19

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

Phase: N/A Priority: Normal
NCT ID: NCT02057718 Org: User:
Start: 03/01/14 End: 05/08/20 Due: 05/08/21

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02057692 Org: User:
Start: 11/24/14 End: 11/16/16 Due: 11/16/17

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT02787304 Org: User:
Start: 10/24/16 End: 07/27/18 Due: 07/27/19

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study

Phase: N/A Priority: Normal
NCT ID: NCT04168385 Org: User:
Start: 01/16/20 End: 09/04/24 Due: 09/04/25

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

Phase: N/A Priority: Normal
NCT ID: NCT02571192 Org: User:
Start: 10/01/15 End: 10/01/15 Due: 10/01/16

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)

Phase: N/A Priority: Normal
NCT ID: NCT02047318 Org: User:
Start: 12/20/13 End: 06/17/20 Due: 06/17/21

A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)

Phase: N/A Priority: Normal
NCT ID: NCT03353454 Org: User:
Start: 10/25/18 End: 06/15/20 Due: 06/15/21

A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

Phase: N/A Priority: Normal
NCT ID: NCT04530994 Org: User:
Start: - End: - Due: -